MM120

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD

Conditions

ADHD, Attention Deficit Disorder

Trial Timeline

Dec 17, 2021 → Dec 4, 2023

About MM120

MM120 is a phase 2 stage product being developed by Definium Therapeutics for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT05200936. Target conditions include ADHD, Attention Deficit Disorder.

What happened to similar drugs?

10 of 20 similar drugs in ADHD were approved

Approved (10) Terminated (2) Active (10)
atomoxetineEli LillyApproved
Strattera (atomoxetine)Eli LillyApproved
Atomoxetine + placeboEli LillyApproved
atomoxetine (Strattera)Eli LillyApproved
🔄dasotraline + PlaceboSumitomo PharmaPhase 3
🔄dasotraline 4mgSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05407064Phase 2Completed
NCT05200936Phase 2Completed

Competing Products

20 competing products in ADHD

See all competitors